Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: subcutaneous allergy immunotherapies - Allergy Therapeutics

Drug Profile

Research programme: subcutaneous allergy immunotherapies - Allergy Therapeutics

Alternative Names: Japanese cedar allergy vaccine - Allergy Therapeutics

Latest Information Update: 19 Dec 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergy Therapeutics
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Allergic rhinitis

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 19 Dec 2014 No development reported - Preclinical for Allergic rhinitis (Prevention) in United Kingdom (SC)
  • 15 Jan 2010 Preclinical development is ongoing in the United Kingdom for an SC injection-based immunotherapy against allergic rhinitis caused by Japanese cedar pollen allergen
  • 01 Feb 2007 Preclinical development is ongoing for SC injection-based immunotherapies against allergy arising from Japanese cedar pollen allergen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top